P-0183 - Bevacizumab Can Be Infused Safely Over 10 Minutes in Metastatic Colorectal Cancer

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Colon Cancer
Rectal Cancer
Presenter Tarik Mahfoud
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors R. Khmamouche Mohamed
  • Department of Medical Oncology, Military Hospital Mohammed V, Rabat/MA



Bevacizumab is a humanized monoclonal antibody that blocks vascular endothelial factor. It demonstrated an efficacy in many cancer types. The standard recommendation of administration is the 90-, 60-, and 30-min infusion sequence for all doses. We evaluated in this study the possibility of reducing infusion time to 10 min for bevacizumab given at 5 or 7.5 mg/kg in metastatic colorectal cancer (MCRC).


All patients who received bevacizumab for MCRC were analyzed. Patients were divided into two groups: Group A (bevacizumab was given in the 90-, 60-, and 30-min infusion sequence) and group B (bevacizumab was given over 10 min). Patients' medical records were used to identify any hypersensitivity reactions (HSR) possibly related to bevacizumab.


There were 76 patients in group A and 82 in group B. In group A, 945 doses of bevacizumab were given (572 doses at 5 mg/kg and 373 doses at 7.5 mg/kg). No HSR occurred in this group. In group B, 1023 doses of bevacizumab were given (662 doses at 5 mg/kg and 361 doses at 7.5 mg/kg). Only two events of HSR grade 2 were reported in the 7.5 mg/kg infusions. Both of them were easily resolved with symptomatic treatment.


Bevacizumab 5 or 7.5 mg/kg in MCRC can be infused safely over 10 min.